Treatment Guidelines for Psoriatic Arthritis

Introduction to Psoriatic Arthritis Treatment

The European League Against Rheumatism (EULAR) 2020 guidelines emphasize that biologics should not be combined with other biologics or JAK inhibitors due to safety concerns and lack of efficacy data 1
The American College of Rheumatology (ACR) and National Psoriasis Foundation (NPF) 2018 guidelines do not support combination biologic therapy in any clinical scenario for psoriatic arthritis 2, 3

For patients with significant skin involvement, the EULAR 2020 guidelines recommend initiating an IL-17 inhibitor (ixekizumab) or IL-12/23 inhibitor as first-line biologic therapy, as these demonstrate superior skin efficacy compared to TNF inhibitors 1, 4
For patients without significant skin involvement, either TNF inhibitors or IL-17 inhibitors can be used as first-line biologic therapy, with no clear hierarchy established between these classes 1, 4
Ixekizumab has demonstrated similar efficacy to adalimumab for musculoskeletal manifestations in head-to-head trials 4
IL-17 inhibitors may increase the risk of mild localized candidiasis and require monitoring for inflammatory bowel disease 1, 4

Tofacitinib should only be considered after inadequate response to at least one biologic DMARD, or when a biologic is not appropriate 1, 4, 5
The 2023 EULAR update maintains this positioning due to significant safety concerns, including increased cardiovascular events, malignancies, and venous thromboembolism observed in patients ≥65 years with cardiovascular risk factors 5
Tofacitinib must be prescribed with methotrexate according to European regulatory approval 1, 4
Safety signals include increased herpes zoster infections and deep vein thrombosis, particularly in older patients with cardiovascular risk factors 1, 4

If ixekizumab (IL-17 inhibitor) fails, the ACR/NPF guidelines conditionally recommend switching to a TNF inhibitor over switching to another IL-17 inhibitor 2, 3
Consider IL-12/23 inhibitor if the patient has concomitant inflammatory bowel disease 2, 3
If multiple biologics have failed, consider tofacitinib as a JAK inhibitor option, provided the patient does not have contraindications 1, 4, 5

Serious infections, including tuberculosis, bacterial, invasive fungal, viral, and opportunistic infections leading to hospitalization or death, are a concern with tofacitinib use 2